A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

This Phase 1 study tests a new drug called GLB-001 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) — blood cancers that have come back or stopped responding to other treatments. **You may be eligible if...** - You are 18 or older with AML or high-risk MDS confirmed by lab testing - Your cancer has relapsed or has not responded to all available treatments - Your overall health and performance status allow you to participate (ECOG 0–2) - Your liver, kidney, and clotting function meet minimum standards - You have a life expectancy of at least 12 weeks **You may NOT be eligible if...** - You have a type of leukemia called acute promyelocytic leukemia (APML) - Your leukemia has spread to the brain or spinal cord - You have taken anticancer therapies in the past month - You have chronic graft-versus-host disease requiring immune-suppressing drugs - You have another active cancer besides AML or MDS - You have had recent major surgery (within 4 weeks) - You have active HIV, Hepatitis B, or Hepatitis C - You are pregnant or breastfeeding - You cannot swallow oral medications Talk to your doctor to see if this trial is right for you.